Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 6 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 2 |
| Innovative R&D Strategies and Models - Introduction | 10 | 2 |
| GBI Research Report Guidance | 10 | 2 |
| Current Challenges in the Pharmaceutical R&D - Declining ROI and Stringent Pricing and Reimbursements, a Major Impediment | 12 | 10 |
| Declining Return on Investment in R&D | 12 | 1 |
| Increasing R&D Costs against Declining NME/BLA Approvals during the Period 1995 2010) | 12 | 1 |
| Reduced Success Rates on R&D for the Pharmaceutical Industry | 13 | 2 |
| R&D Costs Increasing Against Revenue Growth for the Top 10 Pharma Companies | 15 | 1 |
| Adverse Pricing and Reimbursement Regime for New Drugs | 16 | 1 |
| Pressure to Curb Healthcare Costs Driving the Increased Adoption of Stringent Pricing Mechanisms | 16 | 2 |
| Economic Evaluations Gaining Importance as a Key Parameter for Reimbursement Decisions | 18 | 2 |
| Generic Competition and Increasing Number of Patent Challenges | 20 | 2 |
| Major Steps Taken by Pharma Companies to Improve R&D Efficiency | 22 | 6 |
| R&D Components to Concentrate for Increasing Efficiency | 22 | 1 |
| Decrease Cost Short Term Solution | 23 | 1 |
| Improve Returns from Same Level of Output Limited Success Potential Solution | 23 | 1 |
| Increase Output (Number of Drugs) Long Term Solution | 24 | 1 |
| Network R&D Involving External Partners to Complement Internal R&D Capabilities | 25 | 1 |
| Establishing Focus on Niche Markets | 26 | 2 |
| Innovative R&D Strategies and Models - Strategic Consolidations | 28 | 9 |
| Major Industry Consolidations in the Last Decade | 28 | 1 |
| Teva Cephalon: Focus on Branded Drugs | 28 | 1 |
| Deal Rationale | 29 | 1 |
| Novartis Alcon: Diversification | 30 | 1 |
| Background | 30 | 1 |
| Deal Rationale | 30 | 1 |
| Pfizer Wyeth: Safeguarding Revenues against Patent Expiries | 31 | 1 |
| Background | 31 | 1 |
| Rationale | 31 | 1 |
| Roche Genentech: Better Coordination in Product Development | 32 | 1 |
| Background: | 32 | 1 |
| Rationale | 32 | 1 |
| Merck Schering-Plough: Expanding Pipeline Portfolio as well as Presence in High Growth Emerging Markets | 33 | 1 |
| Background | 33 | 1 |
| Rationale | 33 | 1 |
| AstraZeneca MedImmune: Reviving Phase III Pipeline While Accelerating Biologics Strategy | 34 | 1 |
| Background | 34 | 1 |
| Rationale | 35 | 1 |
| Eli Lilly ImClone Systems: Developing a Strong Oncology Pipeline Portfolio to Prevent Revenue Dip after Zyprexa Patent Expiry | 35 | 1 |
| Background | 35 | 1 |
| Rationale | 35 | 2 |
| Innovative R&D Strategies and Models Better Lifecycle Management of Existing Drugs | 37 | 16 |
| Indication Expansion | 37 | 1 |
| Case 1: Bayer s Adalat | 37 | 2 |
| Case 2: Merck s Fosamax | 39 | 2 |
| Case 3: Eisai s Aciphex/Pariet | 41 | 2 |
| Extended/Controlled Release Versions | 43 | 1 |
| Case 1: Johnson &Johnson s Risperdal and Risperdal Consta | 43 | 1 |
| Case 2: Pfizer s Zithromax and Zmax | 44 | 2 |
| Case 3: GlaxoSmithKline s Coreg and Coreg Controlled Release (CR) | 46 | 1 |
| New Formulations | 47 | 1 |
| Case 1: Eisai s Aricept | 48 | 1 |
| Case 2: Johnson &Johnson s Concerta | 49 | 2 |
| Case 3: Takeda s Takepron | 51 | 2 |
| Innovative R&D Strategies and Models Internal Reorganization | 53 | 5 |
| Restructuring the R&D | 53 | 1 |
| GlaxoSmithKline Realigning Focus to Vaccines, Consumer Healthcare and Emerging Markets | 54 | 1 |
| Pfizer Redefining the Research Focus and Outsourcing the Rest | 55 | 1 |
| AstraZeneca Consolidating R&D Facilities with Narrowed Therapeutic Focus | 56 | 1 |
| Sanofi Combining Workforce Consolidation with Externalization to Safeguard Future Revenues | 57 | 1 |
| Innovative R&D Strategies and Models Public-Private Partnerships (PPP) | 58 | 15 |
| What are Public-Private Partnerships? | 58 | 1 |
| PPP in R&D in the Pharmaceutical Industry | 58 | 1 |
| Private-Government Partnerships | 59 | 1 |
| Innovative Medicine Initiative in Europe | 59 | 2 |
| Cooperative Research and Development Agreements in the US | 61 | 1 |
| CRADA for Pharmaceutical R&D | 61 | 1 |
| Advaxis Signs CRADA with Vaccine Branch of NCI | 61 | 1 |
| Oxygen Biotherapeutics Signs CRADA with the US Neval Medical Research Center | 61 | 1 |
| Adamas Signs CRADA with the US Navy | 62 | 1 |
| Proximagen Group Signs CRADA With NINDS For Naluzotan Development | 62 | 1 |
| Small Business Innovation Research Program | 62 | 1 |
| Case Study 1: Optivia Received Grants from the NIH | 63 | 1 |
| Case Study 2: Avexia Biologics Received Grants from NIH | 63 | 1 |
| Case Study 3: MBC Pharma Awarded Grant by NIH | 63 | 1 |
| PPP in India | 63 | 1 |
| Publicly Funded Medicines in the US | 63 | 1 |
| Technology Transfer | 64 | 1 |
| Case Study 1: FluMist Technology Transfer NIAID to Aviron | 65 | 1 |
| Case Study 2: Collaboration between Firocuz and GSK | 66 | 1 |
| Laws Enabling Technology Transfer in the US | 67 | 1 |
| Bayh-Dole Act | 67 | 1 |
| Stevenson-Wydler Technology Innovation Act | 67 | 1 |
| Open-source R&D | 67 | 1 |
| Crowdsourcing | 68 | 1 |
| Applicability of Crowdsourcing to the Pharmaceutical Industry | 68 | 1 |
| Sage Bionetworks Received Funding from Quintiles | 68 | 1 |
| Eli Lilly Announced Phenotypic Drug Discovery Initiative | 68 | 1 |
| Partnership with the Academia | 69 | 1 |
| Case Study 1: Pfizer s Centers for Therapeutic Innovation | 70 | 1 |
| Case Study 2: Collaboration between Pfizer and Washington University | 71 | 1 |
| Case Study 3: Partnership between Sanofi Aventis and Harvard University | 72 | 1 |
| Innovative R&D Strategies and Models Use of Information Technology in R&D | 73 | 8 |
| Effective Data Management Is Critical For R&D Productivity | 73 | 1 |
| CDMS | 74 | 1 |
| Clinical Data Management Outsourcing | 74 | 1 |
| Individual Project Outsourcing Model | 74 | 1 |
| Full Time Equivalent Model | 75 | 1 |
| Functional Service Provider Model | 75 | 1 |
| Deals in Clinical Trial Data Management Outsourcing | 75 | 1 |
| Tata Consultancy Services Eli Lilly | 75 | 1 |
| Cognizant AstraZeneca | 76 | 1 |
| Technology Support Inevitable For Personalized Medicine: The Future Class of Medicines | 77 | 1 |
| Paperless Clinical Trials A Billion Dollar Saving Potential | 78 | 1 |
| Clinical Trial Management System | 78 | 1 |
| Electronic Data Capture | 79 | 1 |
| Using Virtual Technology to Reduce R&D Costs and Time | 80 | 1 |
| Innovative R&D Strategies and Models Outsourcing | 81 | 15 |
| Outsourcing R&D | 81 | 1 |
| Role of CROs in Providing Cost Efficiencies | 81 | 2 |
| Risk Sharing and Strategic Partnerships | 83 | 1 |
| Strategic Partnerships Case Study | 84 | 1 |
| Case 1: Covance s $1.6 Billion Strategic Alliance with Eli Lilly | 84 | 1 |
| Case 2: PPD s Strategic Collaboration with Merck | 85 | 1 |
| Case 3: ICON s Partnership with Eli Lilly | 86 | 1 |
| Case 4: Strategic Alliance between Sanofi Pasteur and Covance | 86 | 1 |
| Risk Sharing Case Study | 87 | 1 |
| Case 1: Quintiles Strategic Alliance to Advance Elisa s Oncology Pipeline | 87 | 1 |
| Profiles of Major Global CROs | 88 | 1 |
| Quintiles Transnational Corp. | 88 | 1 |
| Business Description | 88 | 1 |
| Recent M&A Deals and Strategic Alliances | 89 | 1 |
| Covance Inc. | 89 | 1 |
| Business Description | 90 | 1 |
| Recent M&A Deals and Alliances | 90 | 1 |
| Pharmaceutical Product Development | 91 | 1 |
| Business Description | 91 | 1 |
| Recent M&A Deals and Alliances | 91 | 1 |
| Charles River Laboratories International | 92 | 1 |
| Business Description | 93 | 1 |
| Recent M&A Deals and Alliances | 93 | 1 |
| PAREXEL International | 94 | 1 |
| Business Description | 94 | 1 |
| Recent M&A Deals and Alliances | 95 | 1 |
| Innovative R&D Strategies and Models Outsourcing to Emerging Markets (China, India, Brazil and Russia) | 96 | 60 |
| Rationale to Outsource Discovery Research to Emerging Markets | 96 | 1 |
| Advantages with Emerging Nations in Improvising Discovery Research | 97 | 1 |
| Case Study 1: Merck s Outsourcing Strategy to India and China | 97 | 1 |
| Case Study 2: AstraZeneca s Strategic Partnerships with Jubilant, GVK BIO and WuXi | 98 | 2 |
| Case Study 3: BMS with Biocon | 100 | 1 |
| Case Study 4: Novartis Collaboration with Aurigene | 100 | 1 |
| Case Study 5: Eli Lilly s Collaboration with Hutchison MediPharma | 101 | 1 |
| CROs in China | 101 | 1 |
| Classification of CROs in China | 101 | 1 |
| Number of CROs in China Based on Types of Services Rendered | 102 | 1 |
| CRO Profiles | 103 | 1 |
| BOJI Medicine Services Co. Ltd | 103 | 1 |
| Giant Med-Pharma Services Inc | 104 | 1 |
| InCROM | 105 | 1 |
| Pharmaron | 106 | 1 |
| Venturepharm Service Group (VPS) | 107 | 1 |
| PPD | 108 | 1 |
| CCBR-SYNARC | 109 | 1 |
| Quintiles | 110 | 1 |
| Kendle | 111 | 1 |
| Key Issues | 112 | 1 |
| Access to a Large Patient Population to Encourage Growth of the CRO Market in China | 112 | 1 |
| Easy Recruitment of Patients and Speed of Trials will Drive R&D Outsourcing to China | 112 | 1 |
| Increase in Multinational Sites to Conduct Clinical Trials will drive the Clinical Trial Market in China | 112 | 1 |
| Slow Regulatory Approvals to Restrain the Growth of CRO Industry in China | 113 | 1 |
| Insufficient Communication Platform is a Hurdle to the Growth of the CRO Market in China | 113 | 1 |
| Intellectual Property Issues are not Fully Resolved | 113 | 1 |
| Lack of in depth Training in Good Clinical Practices (GCP) for Health Care Professionals | 113 | 1 |
| CROs in India | 114 | 1 |
| Industry Funded Clinical Trials in India in 2011 | 114 | 1 |
| CRO Locations | 115 | 1 |
| Service Portfolio and Benchmarking of Indian CROs | 116 | 1 |
| CRO Profiles | 117 | 1 |
| Reliance Life Sciences | 117 | 1 |
| Asian Clinical Trials | 118 | 1 |
| Diagnosearch Life Sciences | 119 | 1 |
| Clininvent | 120 | 1 |
| Synchron Research Services Pvt Ltd | 121 | 1 |
| Lambda Therapeutic Research Ltd | 122 | 1 |
| GVK Biosciences Pvt Ltd | 123 | 1 |
| Sristek | 124 | 1 |
| Lotus Laboratories Pvt Ltd | 125 | 1 |
| Veeda Clinical Research Ltd | 126 | 1 |
| Vimta Labs Ltd | 127 | 1 |
| Ecron Acunova | 128 | 1 |
| SIRO Clinpharm Pvt Ltd | 129 | 1 |
| Catalyst Clinical Services | 130 | 1 |
| Key Issues | 131 | 1 |
| Cost of Conducting Clinical Trials in India is approximately 55% of the Cost of Conducting a Clinical Trial in the US | 131 | 1 |
| Availability of Facilities for Conducting Clinical Trials | 131 | 1 |
| Increase in Multinational Sites to Conduct Clinical Trials will drive the Clinical Trial Market in India | 132 | 1 |
| Access to a Large Patient Pool | 132 | 1 |
| Lack of Training for Clinical Trial Professionals | 132 | 1 |
| Quality of Clinical Trial Data | 132 | 1 |
| ICH GCP versus Indian GCP | 132 | 1 |
| Slow Hiring in the Government Regulatory Bodies | 133 | 1 |
| The Need for Proposed Additional Documents for Importing Drugs | 133 | 1 |
| CROs in Brazil | 134 | 1 |
| Clinical Trials Registered in 2010 | 134 | 1 |
| CRO Profiles | 134 | 1 |
| Quintiles | 135 | 1 |
| Covance | 136 | 1 |
| Kendle | 137 | 1 |
| PPD | 138 | 1 |
| PRA International | 139 | 1 |
| Chiltern | 140 | 1 |
| ICON plc. | 141 | 1 |
| Omnicare | 142 | 1 |
| INC Research | 143 | 1 |
| PAREXEL | 144 | 1 |
| Intrials | 145 | 1 |
| Eurotrials | 146 | 1 |
| PGS Medical/Statistics | 147 | 1 |
| Key Issues | 148 | 1 |
| Access to a Large Patient Pool | 148 | 1 |
| Subject Recruitment, Retention and Speed of Trials | 148 | 1 |
| Cost Advantage in Brazil | 148 | 1 |
| Increase in the Number of FDA Regulated Principal Investigators | 149 | 1 |
| Issues Related to Intellectual Property and New Medicine Approval | 149 | 1 |
| Cultural and Socioeconomic Factors Could Cause Problems in Conducting Clinical Research | 150 | 1 |
| CROs in Russia | 150 | 1 |
| Clinical Trials Registered in 2010 | 150 | 1 |
| CRO Profiles | 151 | 1 |
| Synergy Research Group | 151 | 1 |
| Quintiles | 151 | 1 |
| PPD | 151 | 1 |
| ICON | 152 | 1 |
| PAREXEL | 152 | 1 |
| INC Research | 152 | 1 |
| Omnicare Clinical Research | 152 | 1 |
| Pharm-Olam | 152 | 1 |
| FOCUS Clinical Drug Development | 153 | 1 |
| Global Clinical Trials | 153 | 1 |
| PSI | 153 | 1 |
| Key Issues | 154 | 1 |
| Low Cost of Conducting Clinical Trials | 154 | 1 |
| High Patient Recruitment Rate | 154 | 1 |
| High Patient Compliance | 154 | 1 |
| Good In and Out- Patient Facilities | 155 | 1 |
| Increase in the Cost of Experienced Study Staff | 155 | 1 |
| Limited Experience of Newly Qualified Sites | 155 | 1 |
| Innovative R&D Strategies and Models In-licensing, Virtual Pharma and Technology Aggregators | 156 | 4 |
| Virtual Pharma Model | 156 | 1 |
| Case Study 1: OncoHoldings | 157 | 1 |
| Case Study 2: Regenicin | 158 | 1 |
| Case Study 3: NovaQuest | 158 | 1 |
| Technology Aggregators | 158 | 1 |
| Developing Novel Compounds through Licensing | 158 | 1 |
| Ono Pharmaceuticals and Concordia Pharmaceuticals | 158 | 1 |
| AstraZeneca and Nektar | 158 | 2 |
| Innovative R&D Strategies and Models R&D Spin Offs | 160 | 3 |
| Pharma R&D Spin Offs | 161 | 1 |
| Case Study 1: GSK and Convergence Pharmaceuticals | 161 | 1 |